REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor sectio ...

Core Insights - Seer, Inc. reported a 32% year-over-year revenue growth, reaching $4.1 million for Q2 2025, driven by increased product sales and service revenue [4][6] - The company launched the high-throughput Proteograph ONE assay and SP200 automation instrument, enhancing scalability and efficiency [3][9] - Seer aims to transform deep, unbiased proteomics, with its technology now supporting multiple population-scale studies [3] Financial Performance - Revenue for Q2 2025 was $4.1 million, up from $3.1 million in Q2 2024, with product revenue at $2.7 million and service revenue at $1.2 million [4][6] - Gross profit was $2.1 million, resulting in a gross margin of 52% for the quarter [5] - Operating expenses decreased by 21% to $22.6 million, primarily due to a reduction in stock-based compensation [5] Net Loss and Cash Position - The net loss for Q2 2025 was $19.4 million, an improvement from a net loss of $22.9 million in the same period last year [6] - As of June 30, 2025, the company had approximately $263.3 million in cash, cash equivalents, and investments [6][9] Future Guidance - Seer expects full-year 2025 revenue to be between $17 million and $18 million, indicating a 24% growth at the midpoint compared to 2024 [7] Recent Developments - The company announced a collaboration with Korea University for a 20,000-sample population-scale proteomics study using the Proteograph ONE assay [9] - Seer has accelerated third-party validation through impactful data presentations and publications from key opinion leaders at recent conferences [9]

Company Participation - Seer, Inc. will participate in the Canaccord Genuity 45 Annual Growth Conference in Boston, MA [1] - The management is scheduled for a fireside chat on August 13 at 9:00 a.m. Eastern Time [2] Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [3] - The Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software [3] - Seer's technology addresses challenges faced by traditional proteomic methods, which often struggle with inconsistent data and limited throughput [3]

Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomic insights, setting a standard in the field with its innovative technologies [3] - The company offers the Proteograph Product Suite, which integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software to address challenges in traditional proteomics [3] Upcoming Financial Results - Seer, Inc. will report its financial results for the second quarter of 2025 on August 6, 2025 [1] - A conference call will be webcast starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Webcast Information - Live audio of the webcast will be accessible on the Investor section of Seer's website [2] - An archived replay of the event will be available on the company's website after the live event [2]

Core Insights - Seer, Inc. has launched the Proteograph Product Suite, which includes the Proteograph ONE Assay and SP200 Automation Instrument, aimed at enhancing mass spectrometry-based proteomics for large-scale studies [1][2][3] Product Launch and Features - The new Proteograph workflow significantly improves scalability, reproducibility, and affordability of deep proteomic analysis, addressing historical limitations in the industry [2][4] - The streamlined workflow can process over 1,000 samples per week on a single SP200 instrument, doubling throughput without compromising performance [7] - The per-sample cost of proteomic analysis has been reduced by approximately 60% compared to the initial release in 2021, making population-scale mass spectrometry proteomics more accessible [3][7] Impact on Research - The Proteograph ONE workflow enables large-scale biomarker discovery, longitudinal disease studies, and comprehensive multi-center research, facilitating advances in personalized medicine [4][8] - The product suite is expected to drive significant advancements in understanding complex diseases such as Alzheimer's and cancer, as showcased at the ASMS 2025 conference [6][10] Scientific Collaboration and Data Presentation - Seer and its collaborators will present new scientific data at the ASMS 2025, highlighting the transformative impact of the Proteograph Product Suite in various research areas [6][10] - Notable presentations will include studies on dementia classification and cancer biomarker discovery, demonstrating the practical applications of the new technology [10][12] Availability - The Proteograph Product Suite will be commercially available starting June 1, with options for instrument and kit purchases as well as services through the Seer Technology Access Center [13]

Core Insights - Seer, Inc. reported a revenue growth of 37% in Q1 2025, reaching $4.2 million compared to $3.1 million in the same period last year, driven by increased product sales and service revenue [4][6] - The company shipped as many Proteograph instruments in Q1 2025 as it did in all of 2024, indicating strong momentum in product demand [3][9] - Seer expects full-year 2025 revenue to be between $17 million and $18 million, representing a 24% growth at the midpoint compared to 2024 [7] Financial Performance - Product revenue for Q1 2025 was $2.9 million, while service revenue was $1.2 million, contributing to the overall revenue increase [4][13] - Gross profit for the quarter was $2.1 million, with a gross margin of 49% [5][13] - Operating expenses decreased by 14% to $22.8 million, primarily due to lower stock-based compensation and laboratory expenses [5][13] Net Loss and Cash Position - The net loss for Q1 2025 was $19.9 million, slightly improved from a net loss of $20.7 million in the same period last year [6][14] - As of March 31, 2025, the company had approximately $285 million in cash, cash equivalents, and investments [6][9] Strategic Developments - Seer secured a significant contract with a new customer for a 10,000-sample study in collaboration with Discovery Life Sciences [9] - The company is accelerating third-party validation of its platform through an increasing number of customer publications and webinars [9] Market Context - The CEO highlighted the ongoing macroeconomic headwinds affecting the life sciences industry but maintained a long-term vision for the company [3]